ALK and neuroblastoma: Based on data collected from some international studies that included multiple disease cohorts, we can conclude that, among cancer cohorts like IMT and ALCL known to have higher frequency of ALK rearrangements, ORR were much higher, ranging from 56 to 100%35,130–132,140,143 compared to 9 to 20%131,143 observed in cancer cohorts such as neuroblastoma and other tumors where ALK mutation and amplifications are generally more prevalent).